Skip to main content

Safety and Clinical Evaluation of Trastuzumab-dttb + Pertuzumab in Patients with HER2-Positive Breast Cancer

2020 Year in Review - Biosimilars

Real-world data indicate the efficacy and safety profile of the biosimilar trastuzumab-dttb + pertuzumab was consistent with that previously reported for trastuzumab reference + pertuzumab in patients with HER2-positive breast cancer.

Dual inhibition with trastuzumab + pertuzumab in combination with chemotherapy is the standard of care for patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and higher tumor stages. During the 2020 American Society of Clinical Oncology Virtual Scientific Program, the results of a study evaluating the safety and efficacy of the biosimilar trastuzumab-dttb in combination with pertuzumab and chemotherapy were reported.

This case series included 35 female patients with HER2-positive breast cancer who were treated with trastuzumab-dttb + pertuzumab at the Division of Oncology at the Medical University of Graz, Austria, between September 2018 and August 2019. Of the enrolled patients, 8 switched from trastuzumab reference to trastuzumab-dttb; 24 (69%) patients were treated with trastuzumab-dttb + pertuzumab in the neoadjuvant setting.

The study population received a median of 4 (range, 3-7) cycles of trastuzumab-dttb + pertuzumab, received a median cumulative trastuzumab-dttb dose of 1904 mg (range, 1560-2640 mg), and received a median cumulative pertuzumab dose of 2100 mg (range, 1680-3360 mg). Prior to receiving trastuzumab-dttb + pertuzumab therapy, all patients included in the study had a normal baseline left ventricular ejection fraction (LVEF; >50%); median LVEF was 60% (range, 60%-65%). At completion of trastuzumab-dttb + pertuzumab therapy or at last assessment, the median LVEF was 60.0% (range, 58%-62%).

A median absolute LVEF decline of 1% (range, –5%-0%) was observed in 21 patients, which corresponded to a median change of 1.7% (range, –7.7%-0%). LVEF reduction ≤50% was reported in 2 patients (5.7%). Decline in LVEF of ≥10% was not reported. Dose interruptions or terminations resulting from adverse events were reported in 2 patients (diarrhea and appetite loss); trastuzumab-dttb treatment continued on schedule. In the 22 patients evaluable for efficacy, 11 patients achieved a pathologic complete response.

Real-world data from this case series in an academic setting indicate the use of the biosimilar trastuzumab-dttb in combination with pertuzumab was associated with efficacy and safety profiles consistent with those previously reported for trastuzumab reference + pertuzumab in patients with HER2-positive breast cancer.

Reference
Suppan C, et al. ASCO 2020. Abstract e12520.

Get TOP in Your Inbox

Stay up to date with the latest oncology pharmacy news and insights by subscribing to our e-newsletter!

SUBSCRIBE

Related Items